Bs En Iso 11737-1

0 views

Skip to first unread message

Tiana Dubree

unread,

Aug 3, 2024, 5:02:57 PM8/3/24

to niapittiepuff

However, the internal tissues of a healthy animal are normally free of microorganisms. In the health care industry, this and numerous other concerns necessitate sterilization, the process by which environments and health care products are made suitable for interface with patients.

ANSI/AAMI/ISO 11737-1:2018 provides guidance on the enumeration and microbial characterization of the population of viable microorganisms on or in a health care product, component, raw material, or package. It is not applicable to the enumeration of viral, prion, or protozoan contaminants, and the standard does not apply to the microbiological monitoring of the manufacturing environment of health care products.

Bioburden is the sum of the microbial contributions from numerous sources, including raw materials, manufacturing, assembly processes, manufacturing environment, assembly aids, cleaning processes, and packaging of finished products. By directing attention towards these processes, bioburden can be useful for validating sterilization processes, control of manufacturing processes, monitoring raw materials or components, assessing the efficiency of cleaning processes, and an overall environmental monitoring program.

Please note that this American National Standard is an adoption of ISO 11737-1:2018, which was developed by ISO Technical Committee 198, Sterilization of health care products. The United States is one of the ISO members that took an active role in the development of this standard, and U.S. participation in ISO/TC 198 is organized through the U.S. Technical Advisory Group to ISO/TC 198, administered by the Association for the Advancement of Medical Instrumentation (AAMI).

Does this only apply to products manufactured going forward from the date of manufacturing under this new certification or does the compliance apply to those with prior date of manufacturing of such product?

ISO 11737-1:2018 specifies requirements and provides guidance on the enumeration and microbial characterization of the population of viable microorganisms on or in a health care product, component, raw material or package.

Bioburden testing is a critical aspect of microbiological quality control in the pharmaceutical and medical device industries. It involves the quantification of viable microorganisms present on or in a product or component. ISO 11737 is the international standard that provides guidelines for bioburden testing. In this article, we will compare two parts of the ISO 11737 standard: ISO 11737-1 and ISO 11737-2, and explore their respective requirements and applications in bioburden testing.

ISO 11737-1: Determination of Bioburden ISO 11737-1 focuses on the determination of bioburden for products that are intended to be sterilized. It outlines the general principles and procedures for bioburden testing, including sampling methods, incubation conditions, and enumeration techniques. The standard emphasizes the importance of obtaining representative samples and conducting tests under conditions that simulate the intended use of the product.

ISO 11737-2: Estimation of Population of Microorganisms on Products ISO 11737-2 complements ISO 11737-1 by providing guidance on estimating the population of microorganisms on products that are not intended to be sterilized. These products may include non-sterile medical devices, pharmaceuticals, and raw materials. ISO 11737-2 outlines methods for determining bioburden levels and assessing the effectiveness of microbial contamination control measures.

Comparison and Application: While ISO 11737-1 focuses on bioburden testing for sterilized products, ISO 11737-2 addresses the estimation of bioburden on non-sterile products. Both standards aim to ensure the microbial quality of pharmaceuticals and medical devices by providing guidance on sampling, enumeration, and acceptance criteria. Manufacturers must carefully consider the requirements of each standard and tailor their bioburden testing protocols accordingly to achieve compliance and maintain product quality.

Conclusion: Bioburden testing plays a vital role in ensuring the microbiological quality of pharmaceuticals and medical devices. ISO 11737-1 and ISO 11737-2 provide valuable guidance for conducting bioburden testing and assessing microbial contamination risks. By following these standards and implementing robust testing protocols, manufacturers can demonstrate compliance with regulatory requirements and uphold the highest standards of product quality and safety.

ISO 11737-1:2006 specifies requirements and provides guidance for the enumeration and microbial characterization of the population of viable micro-organisms on or in a medical device, component, raw material or package.